This inventor holds 1 USPTO granted patent. Top assignees: Nagase Chemicals Ltd., Nagase Co., Ltd.. Active years: 2000.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2000
Title: The Innovative Journey of Keita Umetsu
Introduction
Keita Umetsu is an accomplished inventor hailing from Tatsuno, Japan. He has made significant contributions to the field of antimicrobial agents through his innovative work with iodopropargyl derivatives. With a growing recognition for his inventions, Umetsu continues to influence the industry.
Latest Patents
Umetsu holds one notable patent focused on "Iodopropargyl derivatives and antimicrobial agents comprising them." This invention showcases his dedication to developing effective antimicrobial solutions, which are vital in various applications, including healthcare and agriculture.
Career Highlights
Throughout his career, Umetsu has had valuable experience working with prominent companies. He has contributed his expertise at Nagase & Company, Ltd. and Nagase Chemicals Ltd. His experience in these organizations has equipped him with a solid foundation in research and development, enabling him to innovate effectively.
Collaborations
In his pursuit of innovation, Umetsu has collaborated with esteemed colleagues, including Yasuo Chikusa and Shigeya Saijo. Their collective efforts have undoubtedly propelled their projects forward, fostering an environment of creativity and knowledge exchange.
Conclusion
Keita Umetsu represents the essence of innovation in the field of antimicrobial agents. With his patent focused on iodopropargyl derivatives, and backed by his experience in reputable companies and collaborations with talented individuals, he continues to make strides in enhancing public health through effective solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile